Is glucagon needed in type 1 diabetes?

The Lancet Diabetes and Endocrinology

Volumn 3, Issue 8, 2015, Pages 578-579

  Castle, Jessica R ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; INSULIN;

ALGORITHM; DEVICE APPROVAL; DISEASE SEVERITY; DRUG DELIVERY DEVICE; DRUG MECHANISM; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN SENSITIVITY; NOTE; PRIORITY JOURNAL; ARTIFICIAL PANCREAS; DIABETES MELLITUS, TYPE 1; FEMALE; INSULIN INFUSION; MALE;

DIABETES MELLITUS, TYPE 1; FEMALE; GLUCAGON; HUMANS; INSULIN; INSULIN INFUSION SYSTEMS; MALE; PANCREAS, ARTIFICIAL;

EID: 84938196545     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00210-7     Document Type: Note

References (12)

1. Weinstock RS, Xing D, Maahs DM, et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. J Clin Endocrinol Metab 2013, 98:3411-3419.
2. Haidar A, Legault L, Matteau-Pelletier L Outpatient overnight glucose control with dual-hormone artificial pancreas, single-hormone artificial pancreas, or conventional insulin pump therapy in children and adolescents with type 1 diabetes: an open-label, randomised controlled trial. Lancet Diabetes Endocrinol 2015, published online June 9. http://dx.doi.org/10.1016/S2213-8587(15)00141-2.
3. Castle JR, Engle JM, El Youssef J, et al. Novel use of glucagon in a closed-loop system for prevention of hypoglycemia in type 1 diabetes. Diabetes Care 2010, 33:1282-1287.
4. Jacobs PG, El Youssef J, Castle J, et al. Automated control of an adaptive bihormonal, dual-sensor artificial pancreas and evaluation during inpatient studies. IEEE Trans Biomed Eng 2014, 61:2569-2581.
5. Haidar A, Legault L, Messier V, Mitre TM, Leroux C, Rabasa-Lhoret R Comparison of dual-hormone artificial pancreas, single-hormone artificial pancreas, and conventional insulin pump therapy for glycaemic control in patients with type 1 diabetes: an open-label randomised controlled crossover trial. Lancet Diabetes Endocrinol 2015, 3:17-26.
6. Van Bon AC, Luijf YM, Koebrugge R, Koops R, Hoekstra JB, DeVries JH Feasibility of a portable bihormonal closed-loop system to control glucose excursions at home under free-living conditions for 48 hours. Diabetes Technol Ther 2014, 16:131-136.
7. Russell SJ, El-Khatib FH, Sinha M, et al. Outpatient glycemic control with a bionic pancreas in type 1 diabetes. N Engl J Med 2014, 371:313-325.
8. Heinemann L, Weyer C, Rauhaus M, Heinrichs S, Heise T Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998, 21:1910-1914.
9. Peyser T, Dassau E, Breton M, Skyler JS The artificial pancreas: current status and future prospects in the management of diabetes. Ann N Y Acad Sci 2014, 1311:102-123.
10. Kovatchev BP, Renard E, Cobelli C, et al. Safety of outpatient closed-loop control: first randomized crossover trials of a wearable artificial pancreas. Diabetes Care 2014, 37:1789-1796.
11. Leelarathna L, Dellweg S, Mader JK, et al. Day and night home closed-loop insulin delivery in adults with type 1 diabetes: three-center randomized crossover study. Diabetes Care 2014, 37:1931-1937.
12. Nimri R, Muller I, Atlas E, et al. MD-Logic overnight control for 6 weeks of home use in patients with type 1 diabetes: randomized crossover trial. Diabetes Care 2014, 37:3025-3032.